The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Eleni-Dimitra Papanagnostou, Magdalini Migkou, Efstathios Kastritis, Panagiotis Malandrakis, Despina Fotiou, Eleni-Dimitra Papanagnostou, Magdalini Migkou, Efstathios Kastritis, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstatios Kastritis and Meletios A. Dimopoulos

INTRODUCTION

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic and has become a major global health concern. The coronavirus genome encodes four different main structural proteins designated as spike (S), envelope, membrane, and nucleocapsid. The virus penetrates through the viral S protein to the angiotensin-converting enzyme 2 (ACE2) receptors that are mainly presented on oral mucosa epithelial cells and lung alveolar type II cells as well as in other human tissues [1, 2]. COVID-19 is a systemic disease with both short- and long-term manifestations [3, 4]. Most of the patients will present with mild or moderate symptoms, although up to 5–10% will present with severe or life-threatening disease course. The development of effective and safe vaccines, as well as novel therapeutics, became a global priority [5, 6].

Immunocompromised patients with hematological malignancies or solid cancer are more susceptible to infection from SARS-CoV-2 and at higher risk of severe complications and worse outcomes compared with the general population [7, 8]. However, there is significant heterogeneity among different cancer subgroups [9]. Patients with hematological malignancies seem to be more susceptible to SARS-CoV-2 with higher morbidity and mortality when compared to patients with solid organ malignancies [10]. Among hospitalized patients with COVID-19 and hematological cancers, the risk of death has been estimated ~39% [10]. Furthermore, lower seroconversion rates following COVID-19 have been reported among patients with solid and hematological cancer compared with convalescent individuals without cancer [11–14].

Patients with multiple myeloma (MM) are at increased risk of infections due to their immunocompromised state, older age, and comorbidities [15]. COVID-19 causes moderate to severe acute respiratory dysfunction in 77% of MM patients and leads to critical condition in ~8% of them [16]. More than 80% of MM patients who are infected by SARS-CoV-2 require hospital admission [17], while almost 33% of hospitalized MM patients with COVID-19 may die because of the infection [8].

Vaccination against SARS-CoV-2 constitutes an important preventive strategy against COVID-19 in patients with MM, in addition to other precaution measures including mask wearing, social distancing, and modifications in the treatment schedule during the pandemic [18, 19]. However, its efficacy in MM is largely unknown [20–22]. In general, patients with MM may present a decreased antibody response following vaccination [23, 24]. This is attributed to defects in immune effector cells, associated with the B-cell disorder and the use of anti-myeloma regimens [14]. The BNT162b2 mRNA and the AZD1222 viral vector vaccines against SARS-CoV-2 have shown significant efficacy in...
healthy adults [25, 26]. The first BNT162b2 dose confers some protection among nursing facility members, health workers, and octogenarians [27–29]. However, low antibody responses have been demonstrated among 48 elderly myeloma patients who received the first dose of the BNT162b2 vaccine [30]. In another study including 42 patients with MM, it was demonstrated that they had suboptimal responses after vaccination with the BNT162b2 mRNA vaccine, especially those on treatment with anti-CD38-based regimens [31]. Regarding ChAdOx1 nCoV-19 vaccine (AZD1222), no data on its efficacy among patients with solid and hematological malignancies are currently available.

In this context, we report here the development of neutralizing antibodies (NAbS) against SARS-CoV-2 in patients with plasma cell neoplasms after vaccination with either the mRNA BNT162b2 or viral vector vaccine AZD1222 vaccine, up to day 50 post their first vaccine dose, and we evaluate possible correlations with clinical characteristics of patients as well as with treatment data.

PATIENTS AND METHODS

Patients and controls

Major inclusion criteria for the participation of patients in this study included: (i) age above 18 years; (ii) presence of monoclonal gammapathy of undetermined significance (MGUS), smoldering myeloma (SMM) who have never received any kind of anti-myeloma therapy or active MM according to International Myeloma Working Group criteria [32], irrespective of the treatment given or the line of therapy; and (iii) eligibility for vaccination, according to International Myeloma Society recommendations [33]. Volunteers of similar age and gender, who served as controls, were also included in this analysis.

Major exclusion criteria for both myeloma patients and controls included the presence of: (i) autoimmune disorder or other active malignant disease; (ii) HIV or active hepatitis B and C infection, (iii) end-stage renal disease, and (iv) prior diagnosis of COVID-19. Relevant data was extracted from the medical records and included: demographics, complete blood count, serum immunoglobulin (lg) levels, disease status, and type of treatment. Dexamethasone administration was held 2 weeks before until 1 week after each vaccine shot.

All participants have been enrolled in a large prospective study (NCT04743388) evaluating the kinetics of anti-SARS-CoV-2 antibodies after COVID-19 vaccination in healthy subjects and in patients with hematological malignancies or solid tumors. The study was approved by the Institutional Ethics Committee of General Hospital Alexandra, Athens, Greece in accordance with the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. All patients and controls provided written informed consent prior enrollment in the study.

NAbS measurement

After vein puncture, the serum of both patients and controls was collected on day 1 (D1; before the first BNT162b2 or AZD1222 dose), on day 22 (D22; before the second dose of the BNT162b2 or 3 weeks post the first AZD1222 dose) and on day 50 (D50; 4 weeks post second dose of the BNT162b2 or 7 weeks post the first AZD1222 dose).

Serum was separated within 4 h from blood collection and stored at −80°C until the day of measurement. NAbS against SARS-CoV-2 were measured using FDA approved methodology (ELISA, cpAss™ SARS-CoV-2 NAb Detection Kit; GenScript, Piscataway, NJ, USA) [34] on the above-mentioned timepoints. A NAb titer of at least 30% is considered as positive, whereas a NAb titer of at least 50% has been associated with clinically relevant viral inhibition [35]. According to FDA, high NAb titer for this specific method is considered any value above or equal to 68%. Samples of the same patient or control were measured on the same ELISA plate.

Statistical analysis

All statistical analyses were performed with STATA (version 17.0, College Station, Texas). All variables were tested for normal data distribution. Normally distributed data were expressed as means ± standard deviation (SD). Non-normally distributed data were presented as the median with the interquartile range (IQR). For categorical variables, the χ² or Fisher exact test were used to compare the distributions for the two randomized groups. Non-paired Student’s t tests were used for between-treatment comparisons of continuous variables. Post hoc mixed-model repeated measures analysis was used to evaluate the neutralizing antibodies over time with cases and controls as main effects and neutralizing antibodies as dependent variables. Mixed models were performed using direct likelihood estimation with fixed effects of groups, time of antibodies and interaction of groups (cases, controls) by timing of antibody measurement. An unstructured covariance matrix was used to model within-patient error. All significance tests were two tailed and conducted at the 5% significance level.

RESULTS

Baseline characteristics of patients and controls

Study population included 276 patients with plasma cell neoplasms (213 symptomatic MM, 38 SMM, 25 MGUS) (151 males/125 females; median age: 74 years, IQR: 62–80 years) and 226 controls matched for age and gender who were vaccinated during the same period, at the same vaccination center (Alexandra Hospital, Athens, Greece).

Two hundred and fifteen patients (77.9%) were vaccinated with the BNT162b2 and 61 (22.1%) with the AZD1222 vaccine. The relative proportion in the control group was similar with the patient group; 171 (75.66%) were vaccinated with the BNT162b2 and 55 (24.34%) with the AZD1222 vaccine (p = 0.56). The median BMI between the two groups was similar [26 (IQR 24–29) for the patient group versus 27 (IQR 23–30) for the control group, p = 0.8]. Forty-two patients (15.22%) had lymphopenia (<1000 lymphocytes/mm³), of which 40 out of 42 were symptomatic MM patients. At the time of vaccination 34 (12.32%) patients with MM were not receiving active treatment.

The baseline characteristics of the enrolled patients are depicted on Table 1.

Humoral response in patients and controls

On D1 there was no difference regarding the NAb titer between patients and controls (p = 0.7). After the first dose of the vaccine, on D22, the patient group had lower NAb titers compared with controls: the median NAb inhibition titer was 27% (IQR: 15.3–42%) for patients versus 38.7% (IQR: 22–54.3%) for controls; p < 0.001 (Fig. 1). More, specifically, 117 (42.4%) patients versus 145 (64.2%) controls developed NAb titers ≥30% on D22 (p < 0.001). The respective number of patients and controls who developed NAb titers ≥50% (clinically relevant viral inhibition) was 55 (19.9%) and 73 (32.3%), respectively (p = 0.002). There was no difference between patients who received the BNT162b2 or the AZD1222 vaccine in terms of the values of NAbS titers on D22, or the number of patients who developed NAbS titers ≥30% or ≥50%. On D50, 4 weeks after the second dose of the BNT162b2 vaccine or 7 weeks after the first dose of AZD1222, the patient group continued to have lower NAb titers compared with controls: the median NAb inhibition titer was 62.8% (IQR: 26–88.9%) for patients versus 90% (IQR: 58–96.4%) for controls; p < 0.001 (Fig. 1). More, specifically, 196 (71%) patients versus 204 (90.3%) controls developed NAb titers ≥30% on D50 (p < 0.001). The respective number of patients and controls who developed NAb titers ≥50% was 158 (57.3%) and 183 (81%) (p < 0.001). Out of these 158 patients, 114 had symptomatic MM, 23 asymptomatic MM, and 21 MGUS and among patients with different plasma cell dyscrasias, 53.5% of symptomatic myeloma patients, 84% of MGUS and 60.5% of those with SMM achieved clinically relevant antibody response (p = 0.013). MGUS patients had no differences from controls regarding the development of Nabs titers of ≥30% or ≥50% on D50.

When we compared only the symptomatic MM patients with the control group, the median NAb inhibition titer was inferior among MM patients compared with controls both on day 22 (25.9%, IQR: 14.6–39.5%, versus 55.7%, IQR: 25–84.8%, p < 0.001, respectively) and on day 50 (38.7%, IQR: 22–54.3% versus 90.6%, IQR: 58.1–96.4%, p < 0.001, respectively) (Fig. 2). When we
Baseline characteristics of patients with MM/SMM/MGUS.

| Number of patients | N = 276 |
|--------------------|---------|
| MM n = 213 | (77.2%) |
| SMM n = 38 | (13.7%) |
| MGUS n = 25 | (9.1%) |
| Gender | Male n = 151 (54.7%) |
| | Female n = 125 (45.3%) |
| Age in years, median (range) | 74 (IQR: 62–80) |
| BMI, median (range) | 26 (IQR: 24–29) |
| Comorbidities | Pulmonary disease: n = 18 (6.6%) |
| | Diabetes mellitus: n = 39 (14.3%) |
| | Autoimmune disease: n = 6 (2.3%) |
| | Cardiovascular disease: n = 149 (54.1%) |
| Total lymphocyte count, median (range), cells/mm³ | 1400 (110–2000) |
| Lymphopenia (<1000 cells/mm³) | n = 42 (15.2%) (n = 40 MM) |
| Immunoglobulins, median (range), mg/dl | IgG: 939 (529–1300) |
| | IgA: 99 (37–217) |
| | IgM: 27.5 (19–55) |
| Immunoparesis 1 IgG < 700 mg/dl | n = 85 (81 MM, 3 MGUS, 1 SMM) (30.8%) |
| Immunoparesis 2 IgA < 70 mg/dl | n = 112 (98 MM, 2 MGUS, 12 SMM) (40.6%) |
| Immunoparesis 3 IgM < 40 mg/dl | n = 32 (32 MM) (11.5%) |
| Ig type | IgA n = 30 (10.8%) |
| | IgG n = 171 (62%) |
| | IgM n = 6 (2.1%) |
| KLC | n = 59 (21.5%) |
| LLC | n = 10 (3.6%) |
| MM | ISS-1 n = 83 (39.1%) |
| | ISS-2 n = 74 (34.9%) |
| | ISS-3 n = 55 (26%) |
| | R-ISS-1ª n = 41 (27.5%) |
| | RISS-2 n = 88 (59%) |
| | RISS-3 n = 20 (13.5%) |
| MM Treatment line, median (range) | 2 (IQR: 1–3) |

| Cyclophosphamide-Dexamethasone | n = 1 (0.4%) |
| Vaccination with BNT162b2 | n = 215 (77.8%) |
| Vaccination with AZD1222 | n = 61 (22.2%) |

*Available data for RISS only for 149 patients.

MM multiple myeloma, SMM smoldering multiple myeloma, MGUS monoclonal gammopathy of undetermined significance, BMI body mass index, ISS International Staging System, R-ISS Revised International Staging System, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, KLC kappa light chain, λLC lambda light chain, PI proteasome inhibitor; IMID immunomodulatory drug.

Compared MM patients with SMM and MGUS on day 22 and day 50, there was no significant difference regarding the NAb production between the group of MM and SMM at all timepoints. On the contrary, there were significant differences in NAb responses between MM and MGUS at both timepoints (mean difference 14%, p = 0.009, on day 22 and 21.59%, p = 0.003, on day 50, respectively) (Fig. 3).

Predictive factors for NAb production

Among the 114 MM patients with clinically relevant response on day 50 (i.e. with NABs titers ≥50%), 23 (20.2%) were in remission, without receiving any therapy (in complete or partial remission) and 91 were on treatment (Table 2). All patients in remission had normal uninvolved immunoglobulins levels post treatment completion and had not received treatment for more than 6 months. Among symptomatic MM patients with low response rates (<30%) on day 50 (n = 65), only 2 were off treatment, while 63 were on active treatment (Table 2).

On day 22, there was no significant difference in NAb production among the different myeloma treatment groups. On the other hand, on day 50, patients who did not receive any treatment achieved significantly higher NABs responses (mean ± SD: 66% ± 25.4%) compared with the patients receiving belantamab mafodotin-based combinations (mean ± SD: 28.2% ± 20.1%, p = 0.002, ANOVA pair group comparison) or anti-CD38-based combinations (mean ± SD: 45.4% ± 29.4%, p = 0.013, ANOVA pair group comparison). Similar differences were identified for the lenalidomide maintenance group compared with the belantamab and anti-CD38 groups (p = 0.003 and p = 0.015, respectively, ANOVA pair group comparisons).

When we compared the group of patients on treatment with belantamab mafodotin or anti-CD38 monoclonal antibodies with those receiving other treatment regimens and those who did not receive any treatment, there was a decreased median NAb titer on day 50 for the belantamab/anti-CD38 group compared with the other two groups. More specifically, the median NAB titer was 31.9% (IQR: 18.9–69) for the belantamab/anti-CD38 group compared with 62.8% (IQR: 26–88.3%) for the other treatment group (p = 0.005) and 64.6% (IQR: 47.6–90.8%) for the off-treatment group (p = 0.001) (Fig. 4). No other significant findings were noted among treatment groups on day 50.

Furthermore, we sought to investigate predictive factors for NAB titers less than 50% among patients with symptomatic MM on day 50 (Table 3). Age, BMI, ISS, and RISS were not proven as statistically significant in the univariate analysis. On the contrary, treatment type and, more specifically, the combinations based on belantamab mafodotin and anti-CD38 monoclonal antibodies were significant predictive factors for lower antibody response (OR: 9.4, 95% CI: 1.7–51.1, p = 0.009, and OR 2.9, 95% CI: 1.2–7.1, p = 0.002, respectively). The presence of lymphopenia at the time of vaccination was also a significant predictive factor for decreased humoral response (OR: 3.5, 95% CI: 1.8–6.7, p =...
0.019), as well as the low levels of IgA (OR: 2.9, 95% CI: 1.8–4.4, \( p = 0.024 \)). Female gender was predictive for superior NAb production on day 50 compared with males (OR: 0.6, 95% CI: 0.4–0.9). Importantly, the multivariate analysis showed that treatment with combinations based on belantamab mafodotin (OR 7.6, 95% CI: 1.4–42.4 \( p = 0.021 \)) and lymphopenia (OR: 2.1, 95% CI: 1.0–4.5, \( p = 0.048 \)) were the only significant predictive factors for NAb response on day 50. There was also a trend towards increased

Fig. 1  Kinetics of NAbs in MM/SMM/MGUS patients compared with age- and sex-matched controls after vaccination with 2 doses of the BNT162b2 or 1 dose of the AZD1222 vaccine. Patients had significantly lower NAbs titers on day 22 and on day 50 compared with controls.

Fig. 2  Kinetics of NAbs in patients with symptomatic MM compared with age- and sex-matched controls after vaccination with 2 doses of the BNT162b2 or 1 dose of the AZD1222 vaccine. Patients with MM had significantly lower NAbs titers on day 22 and on day 50 compared with controls.
risk for poor NAb response following COVID-19 vaccination with anti-CD38-based regimens (OR: 2.4, 95% CI: 2.9–6.2, p = 0.07) (Table 3). At this point, we need to stress that almost 85% of patients under daratumumab-based regimens were at the monthly administration schedule of daratumumab.

We subsequently examined if there was any effect of the line of therapy (two versus more than two lines of therapy or three versus more than three lines) and there was no influence of the line of therapy on the development of NAbs in all studied timepoints.

**Adverse events**

Seventy-one (33%) and 68 patients (31.6%) reported mild reactions after the first and second dose of the BNT162b2 vaccine, respectively. Twenty (32.8%) patients vaccinated with the first dose of AZD1222 also presented with local reactions. These reactions included mainly pain at the site of the injection, erythema, and/or swelling. The rate of this adverse event between the first and second dose of the BNT162b2 was not statistically significant (p = 0.7). In all, 13% (n = 28) and 21% (n = 45) of the patients vaccinated with the BNT162b2 vaccine reported systemic adverse reactions but all were categorized as mild (grade 1 or 2). The systemic adverse events included fatigue, fever, lymphadenopathy, muscle pain, arthralgias, and headache. The presence of the adverse events was independent of the active treatment or disease status.

**DISCUSSION**

Our data indicate that vaccination with either the BNT162b2 mRNA or the AZD1222 viral vector vaccine leads to a less intense humoral response, as reflected by a lower production of NAbs, against SARS-CoV-2 among patients with MM/SMM compared with healthy controls of similar age and gender and without malignant disease. However, patients with MGUS did not have significant differences compared with healthy controls. Our findings were independent of the vaccine type on D22, where we could perform a fair comparison (3 weeks after the first vaccine dose; on D50 patients had received two doses of BNT162b2 but only one dose of AZD1222). Active treatment with regimens including belantamab mafodotin or anti-CD38 monoclonal antibodies that deplete B-cells, as well as lymphopenia, were negative prognostic factors at the multivariate analysis, as they were correlated with lower antibody response rates. To our knowledge, this is the first report to demonstrate the kinetics of NAbs-mediated humoral response in patients with MM after 2 doses of vaccination with the BNT162b2 vaccine and the first dose of AZD1222.

The underlying causes for low humoral response to vaccination in patients with plasma cell dyscrasias are multifactorial and it seems

---

**Fig. 3** Kinetics of NAbs in MM compared with SMM and MGUS after vaccination with 2 doses of the BNT162b2 or 1 dose of the AZD1222 vaccine. A statistically significant difference was identified both on day 22 and day 50 between the MM and MGUS group.

---

| Table 2. Type of treatment for NAbs responders and non-responders on day 50. |
|-----------------|-----------------|-----------------|
|                  | NAbs >50% (n = 114) (%) | NAbs <30% (n = 65) (%) |
| Off treatment    | 23 (20.2)        | 2 (3.1)         |
| Belantamab mafodotin monotherapy | 0              | 2 (3.1)         |
| Belantamab mafodotin combinations | 2 (1.7)       | 5 (7.7)         |
| Daratumumab monotherapy | 2 (1.7)       | 6 (9.2)         |
| Daratumumab + PI combinations | 5 (4.4)       | 9 (13.9)        |
| Anti-CD38 antibodies + IMID combinations | 14 (12.3)    | 9 (13.9)        |
| Other anti-CD38 combinations | 2 (1.8)        | 1 (1.5)         |
| IMID-based regimens | 11 (9.6)       | 9 (13.9)        |
| PI-based regimens | 6 (5.2)         | 7 (10.7)        |
| IMID and PI combinations | 25 (21.9)    | 10 (15.3)       |
| Lenalidomide maintenance | 23 (20.3)     | 5 (7.7)         |
| Cyclophosphamide | 1 (0.9)         | –               |

*PI proteasome inhibitor, IMID immunomodulatory drug.*
that both disease-related immune dysregulation and therapy related immunosuppression are involved [23]. Interestingly, both MM and SMM patients showed a suboptimal humoral immune response following vaccination, suggesting that the disease itself plays a crucial role in immunosuppression of these patients. Myeloma cells suppress normal B-cell expansion and immunoglobulin production. MM is a de novo immunological disease with impaired function of immune cells in the marrow microenvironment characterized by dysfunction of effector cells, loss of antigen presentation and expansion of immunosuppressive cells [36]. Memory B-cell and T-cell responses might be significantly compromised in patients with MM [37]. Furthermore, anti-myeloma B-cell depleting therapies may impair immune response to vaccines, whereas both myeloma microenvironment and anti-myeloma treatment may impair T-cell function as well [23].

Patients with MM often present suboptimal seroconversion rates after a single-dose vaccine against bacteria and viruses and, therefore, booster doses are needed to assure adequate protection, such as the case with the seasonal flu vaccine [23]. A single dose of inactivated influenza vaccine in patients with MM result in a low seroconversion rate reaching 20–25% [38]. Interestingly, studies that evaluated the role of a booster influenza dose demonstrated increased immunity reaching at 70% [39, 40]. Active disease and active treatment were associated with lower response rates.

These results are in accordance with our study demonstrating the low humoral response with the COVID-19 vaccines. Patients receiving anti-myeloma treatment without any anti-CD38 regimens were more likely to respond to vaccination. On the other hand, daratumumab- or isatuximab-based and anti-BCMA-based regimens were significantly associated with decreased NAb responses, probably due to a direct effect on the immune system. Anti-CD38 monoclonal antibodies and anti-BCMA compounds directly reduce immunogenicity by depleting antibody-producing B-cells [41–44]. However, a recent study showed that antibody production against Hemophilus Influenzae B, seasonal influenza, and Streptococcus pneumoniae was not compromised when the vaccination was performed at least 2 months post the last dose of daratumumab [45]. On the contrary, IMiDs promote the activation of the immune system especially via T and NK cells enhancement, cytokine increase, decreased Treg activity and enhancement of dendritic cells and antibody-dependent cell-mediated cytotoxicity, which is also supported by our results regarding COVID-19 vaccination [46, 47]. In the light of our findings, it may be eloquently supported that a booster dose may be needed to enhance humoral response, especially for patients with MM on treatment with B-cell depleting therapies. If possible, a delay in treatment initiation with such anti-myeloma drugs might be also considered on a tailored basis until the vaccination is completed. Further studies including higher patient numbers may be necessary to determine the optimal dosing, dosing intervals, and number of boosting doses in these patients, as well as treatment-specific intervals before vaccination.

Furthermore, hypoglobulinemia has been associated with inferior antibody responses among patients with other hematological malignancies and COVID-19 [14]. In our study, it has been confirmed that patients with increased humoral responses did not experience immunoparesis. Furthermore, it seems that patients who completed their treatment and remained on response at the time of vaccination were more likely to produce NAb and this is probably related to a reconstitution of humoral immunity.

Interestingly, it has been previously shown that the production of NAb titers at a level of ≥50% on D22 after the first BNT162b2 dose was low even among healthy individuals aged 65–85 years [35]. However, higher antibody titers after a single dose of mRNA-based vaccine against SARS-CoV-2 have been detected in individuals who have recovered from COVID-19 [48]. Since our results denote that patients with plasma cell dyscrasias have blunted antibody responses, they also suggest that the second timely vaccine dose is necessary for this subpopulation with a
malignant hematological disease that deregulates the immune homeostasis. In accordance to a previous study on healthy individuals [49], our results advocate for an earlier administration of the second dose of the AZD1222 especially for patients with MM. It is worth mentioning that our study included only one dose of AZD1222, and, thus, firm conclusions cannot be drawn regarding the humoral response after the full vaccination schedule with this vaccine type. It should be also highlighted that patients with MM and SMM presented with a similar humoral response profile, while patients with MGUS achieved superior antibody responses similar to healthy individuals. Further studies will elucidate if this can be a discriminatory factor regarding the need for booster doses.

One of the main strengths of our study is the evaluation of NABs, which have been shown to have an important predictive value of immune protection from symptomatic COVID-19 in a recent study [50]. Therefore, NAB levels can be considered valuable surrogates of vaccine efficacy. The main limitations of our study include the relevant limited number of patients in the subgroup analyses, the absence of data on T-cell induced immune responses following vaccination against SARS-CoV-2 and the short follow up period that was not enough to determine the role of vaccination against clinically important COVID-19 infection in patients with plasma cell dyscrasias. In general, the vaccine protection against severe COVID-19 and reinfection by SARS-CoV-2 variants for patients with hematological cancer has not been elucidated yet.

In conclusion, patients with myeloma have an inferior humoral response against SARS-CoV-2 after COVID-19 vaccination compared with healthy individuals. Although humoral immunity seems to be deregulated, mucosal surface antibodies, such as IgA, and protective T-cell responses, might particularly important in the protection following natural SARS-CoV-2 infection or vaccination [51, 52]. Further studies on the kinetics of immune subpopulations following COVID-19 vaccination will elucidate the underlying immune landscape and determine the potential need for additional booster doses or protective administration of antibodies against SARS-CoV-2 in patients with plasma cell dyscrasias and no/poor response after full vaccination. For these patients prolonged self-protection measures, such as mask wearing and social distancing, are necessary. Finally, the effect of the long-term safety of these vaccines seems reassuring, however close monitoring is required especially in patients with plasma cell dyscrasias, considering the increased risk for concurrent or synergistic adverse events.

**REFERENCES**

1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e278.
2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:81–92.e286.
3. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493–506.
4. Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect. 2021;83:1–16.
5. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Mikhaylo M, Tzaninis IG, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2020;21:167–79.
6. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–60.
7. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Huabei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:904–13.
8. Chari A, Samur MK, Martinez-J Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–40.
9. Chamilos G, Lionakis MS, Kontoyiannis DP. Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)? Clin Infect Dis. 2021;72:351–6.

---

**Table 3.** Univariate and multivariate analysis for NAbs titers <50% among patients with symptomatic MM on day 50.

| Variable                        | Univariate analysis OR, 95% CI | Multivariate analysis OR, 95% CI |
|---------------------------------|-------------------------------|---------------------------------|
| Age                             | 0.99, 0.98–1.01               | –                               |
| Gender                          | –                             | –                               |
| Males (reference)               | –                             | –                               |
| Females                         | 0.6, 0.4–0.9                  | –                               |
| BMI                             | 1.03, 0.98, 1.09               | –                               |
| Disease type (vs. controls)     | Omitted due to collinearity   | –                               |
| Multiple myeloma                | 3.7, 2.4–5.7                  | –                               |
| MGUS                            | 0.8, 0.3–2.5                  | –                               |
| Smoldering multiple myeloma     | 2.8, 1.3–5.8                  | –                               |
| ISS                             | –                             | –                               |
| Stage I (reference)             | –                             | –                               |
| Stage II                        | 0.76, 0.4–1.4                 | –                               |
| Stage III                       | 1.5, 0.8–3.0                  | –                               |
| RISS                            | –                             | –                               |
| Stage I (reference)             | –                             | –                               |
| Stage II                        | 1.7, 0.8–3.5                  | –                               |
| Stage III                       | 1.7, 0.6–5.1                  | –                               |
| Myeloma type                    | –                             | –                               |
| IgG (reference)                 | –                             | –                               |
| IgA                              | 1.07, 0.5–2.3                 | –                               |
| IgM                              | 0.75, 0.1–4.7                 | –                               |
| KLC                             | 1, 0.4–2.5                    | –                               |
| LLC                             | 1.9, 0.7–3.5                  | –                               |
| Lymphopenia (<1000 cells/cm³)   | 3.5, 1.8–6.7                  | 2.1, 1–4.5                      |
| Immunoparesis                   | –                             | –                               |
| IgA<70 mg/dl                    | 2.9, 1.8–4.4                  | –                               |
| IgM<40 mg/dl                    | 1                             | –                               |
| IgG<700 mg/dl                   | 1.7, 0.4–3.1                  | –                               |
| Treatment type                  | –                             | –                               |
| Off-treatment (reference)       | –                             | –                               |
| Anti-BCMA-based regimens        | 9.4, 1.7–51.1                 | 7.6, 1.4–42.4                   |
| Anti-CD38-based regimens        | 2.9, 1.2–7.1                  | 2.4, 2.9–6.2*                   |
| PI/IMID-based combinations      | 1.8, 0.8–4.3                  | –                               |
| Lenalidomide maintenance        | 0.9, 0.3–2.6                  | –                               |

*MM multiple myeloma, BMI body mass index, ISS International Staging System, R-ISS Revised International Staging System, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, PI proteasome inhibitor, IMID immunomodulatory drug, OR odds ratio, CI confidence interval.

**Italics denote statistical significance.**
10. Vijenthira A, Gong YF, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.

11. Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Ann Oncol. 2021;32:1319–32.

12. Liu Y, Zeng G, Tao H, Shi Y. COVID-19 in Cancer Patients Research Group, Wang T, et al. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer. 2020;147:3267–9.

13. Solodky ML, Galvez C, Russias B, Detourbet P, Nguyen-Bonin V, Herr AL, et al. Lower detection rates of SARS-CoV-2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann Oncol. 2020;31:1087–8.

14. Roeker LE, Knoor DA, Sassinis MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–9.

15. Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, et al. A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the first trial. Leukemia. 2018;32:1404–13.

16. Martinez-Lopez J, Mateos MV, Encinas C, Sureda A, Hernandez-Rivas JA, Lopez de la Guia A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:1013.

17. Engelhardt M, Shoumariyeh K, Rösner A, Ihorst G, Biavasco F, Meckel K, et al. Clinical characteristics and outcome of multiple myeloma patients with concurrent COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica. 2020;105:2872–8.

18. Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34:2000–11.

19. Terpos E, Ntanasis-Stathopoulos I. Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2020;193:1034–1043.

20. Gavirotiapoulotou M, Ntanasis-Stathopoulos I, Korompiki E, Terpos E, Dimopoulos MA. SARS-CoV-2 vaccines in patients with multiple myeloma. Hemasphere. 2021;5:e547.

21. Ludwig H, San-Miguel J, Munsell N, Sonneveil P, Mateos M-V, Moreau P, et al. COVID-19 vaccination in patients with multiple myeloma: focus on immune response. Am J Hematol. 2021;96:896–900.

22. Korompiki E, Gavirotiapoulotou M, Kontoyiannis DP. COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization. JAMA Oncol. 2021. https://doi.org/10.1001/jamaoncol.2021.1218.

23. Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35:31–44.

24. Girimena C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84–94.

25. Polack FP, Thomas SJ, Kitchin N, Guyton-Brenn V, Herr AL, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;382:2605–15.

26. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatli PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91.

27. Ghapure R, Patel A, Link-Gelles R. First-dose COVID-19 vaccination coverage among skilled nursing facility residents and staff. JAMA. 2021:325:1670–1.

28. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and neutralization antibody titers after a single vaccine dose in healthy care workers previously infected with SARS-CoV-2. JAMA. 2021;325:1467–9.

29. Terpos E, Troupakos IP, Karalis V, Ntanasis-Stathopoulos I, Sklirou AD, Bagratuni T, et al. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021. https://doi.org/10.1002/ajh.26248.

30. Khoury DS, Cromer D, Reynolds A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11.

31. Le Bert N, Tan AT, Kunasegaran K, Tham C, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–62.

32. Kostopoulos IV, Orolagas-Stavrou N, Rousakis P, Panteli C, Ntanasis-Stathopoulos I, Charitaki I, et al. Recovery of innate immune cells and persisting alterations in adaptive immunity in the peripheral blood of convalescent plasma donors at eight months post SARS-CoV-2 infection. Microorganisms. 2021;9:546.

ACKNOWLEDGEMENTS

We thank Ioanna Charitaki, RN; Amilia D. Sklirou, PhD; Tina Bagratuni, PhD; Nikoletta Patseas, PhD and Filia Apostolakou, PhD for administrative, technical, or material support. We also thank SYN-ENOSIS (Greece), IEMBITHEK (Greece), Genesis (Greece),
and Nikolao and Theano Vafeia for partially funding this study, as well as all of the study participants for donating their time and samples.

AUTHOR CONTRIBUTIONS
ET, IPT, and MAD designed the research and had the supervision of the study. MG, INS, and AB performed the statistical analysis. MG, INS, AB, SG, PM, DF, EDP, MM, FT, MR, EEP, NK, and EK performed the clinical investigation and the experiments. ET and MG wrote the first draft. All authors revised the draft and agreed with the final version.

CONFLICT OF INTEREST
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to E.T.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.